Q2-Header_1280x350_8

Biomarker Testing Services

by Rules-Based Medicine, a Q² Solutions Company

The industry leader in multiplex immunoassay development and testing

Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA-certified biomarker testing laboratory developing immunoassays used to quantify protein biomarkers in support of drug mechanism of action, pharmacodynamic, prognostic, and predictive clinical studies across all stages of drug discovery and development. RBM is the world’s leading multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (Simoa™) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX.

What differentiates Rules-Based Medicine from its competitors is that they have spent over 20 years internally developing and manufacturing multiplex immunoassays validated to clinical laboratory standards for the Luminex xMAP® technology. Since 2014, they have applied these skills to building ultrasensitive immunoassays on the Simoa™ platform to quantify protein biomarkers previously difficult or impossible to measure. The RBM platform appropriately combines Luminex and Simoa™ microsphere-based immunoassays with the precision and dependability of automated liquid handling systems, advanced quality monitoring, validated data reporting processes, and a highly trained and dedicated staff including project managers. Together these features set RBM apart from other biomarker testing laboratories by providing the highest quality, cost-effective approach to measuring biomarkers from a variety of biological samples.

Why Choose Rules-Based Medicine for your Clinical Trial?

  • Long history of developing, validating, and manufacturing immunoassays allows us to provide customers with unmatched expertise in the field of protein biomarker testing.
  • Quality control measures in place for each and every step of the process, all in accordance with their strict standard operating procedures.
  • Four step quality control procedure including instruments diagnostics, calibrator curves at front and back end of each reaction plate, three levels of controls run in duplicate, and sample review.
  • TruCulture® – An integrated whole-blood collection and leukocyte culture system tube for immunophenotyping at clinical trial sites.

   

to learn more, visit: Rules-Based Medicine website

Related Thought Leaders Insights


Renal Function and Race in Clinical Trials

The glomerular filtration rate (GFR) is a critical indicator of kidney function, and its value may be measured using a simple blood test for creatinine. Historically, studies have shown that people...

Unlocking the power of genomic research with IQVIA bioinformatic capabilities

Presentation by Joanne Hackett, Head of Genomic and Precision Medicine, IQVIA and David Latto, Associate Director, Science Liaison, Q2 SolutionsJoanne and David provide an overview of IQVIA and Q2...

Verified Genomic Reference Samples for Testing Low to Very Low AF Small Variants in OncoPanels and Liquid Biopsy Assays

Although reference samples with known ground truth regarding variants have been around for a while (NIST genome-in-a-bottle samples, HapMap samples, etc.), none have variants in large number...